Frazier Life Sciences led a $53m Series C round in 35Pharma.

Frazier Life Sciences, a healthcare investment firm, led a $53m Series C round in 35Pharma, a clinical-stage biopharmaceutical company developing TGF-beta superfamily therapeutics, with participation from Vivo Capital, Janus Henderson Investors, Deep Track Capital, Paradigm BioCapital Advisors, Columbia Threadneedle, VenBio, Surveyor Capital, Logos Capital and Marshall Wace. "We are delighted to close this Series C financing, which brings multiple new marquee healthcare investors into our cap table. This financing is intended to support initial clinical proof-of-concept studies for HS135 in pulmonary hypertension, as well as advance HS235 - our candidate for the treatment of HFpEF and obesity - through a Phase 1 proof-of-biology trial in obese and overweight healthy volunteers," Ilia A. Tikhomirov, 35Pharma CEO.